• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直肠癌中CD44v6的瘤内异质性。

Intratumoral heterogeneity of CD44v6 in rectal cancer.

作者信息

Liu H-G, Lv L, Shen H

机构信息

Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou Road No. 1838, Guangzhou, 510515, China.

Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Shatai Road No. 1023, Guangzhou, 510515, China.

出版信息

Clin Transl Oncol. 2017 Apr;19(4):425-431. doi: 10.1007/s12094-016-1542-9. Epub 2016 Aug 23.

DOI:10.1007/s12094-016-1542-9
PMID:27553603
Abstract

PURPOSE

CD44v6 plays a controversial role in tumor progression and patient outcome in colorectal cancer by plenty of conflicting reports. The purpose of this study was to profile the intratumoral heterogeneity of CD44v6 in rectal cancer and investigate its role in lymph node metastasis.

METHODS

Sixty patients were included in this study. Immunohistochemistry for CD44v6 was performed in normal mucosa, primary tumor, and lymph node metastasis with whole tissue sections. The staining intensity in tumor center and invasive front was separately measured. Sampling bias was evaluated by quantitative real-time PCR with 15 pairs of frozen tissues from different sites of the primary tumor.

RESULTS

CD44v6 expression increased from normal mucosa to primary tumor to lymph node metastasis. Multiple intratumoral staining patterns was observed in primary tumor, and CD44v6 expression in invasive front was significantly higher than that in tumor center. In addition, mRNA expression levels differed across different geographical regions of the tumor. No association between CD44v6 expression and lymph node metastasis was revealed.

CONCLUSIONS

Substantial intratumoral heterogeneity of CD44v6 exists in rectal cancer that impacts the outcome of individual studies. CD44v6 expression should be assessed in a more precise way with a specified staining pattern and in a designated location.

摘要

目的

众多相互矛盾的报道表明,CD44v6在结直肠癌的肿瘤进展和患者预后中发挥着有争议的作用。本研究旨在剖析直肠癌中CD44v6的肿瘤内异质性,并探究其在淋巴结转移中的作用。

方法

本研究纳入60例患者。采用全组织切片对正常黏膜、原发性肿瘤及淋巴结转移灶进行CD44v6免疫组织化学检测。分别测量肿瘤中心和浸润前沿的染色强度。利用15对来自原发性肿瘤不同部位的冷冻组织,通过定量实时PCR评估抽样偏差。

结果

CD44v6表达从正常黏膜到原发性肿瘤再到淋巴结转移逐渐升高。在原发性肿瘤中观察到多种肿瘤内染色模式,且浸润前沿的CD44v6表达显著高于肿瘤中心。此外,肿瘤不同地理区域的mRNA表达水平存在差异。未发现CD44v6表达与淋巴结转移之间存在关联。

结论

直肠癌中存在大量CD44v6肿瘤内异质性,这影响了个体研究的结果。应采用特定的染色模式并在指定位置以更精确的方式评估CD44v6表达。

相似文献

1
Intratumoral heterogeneity of CD44v6 in rectal cancer.直肠癌中CD44v6的瘤内异质性。
Clin Transl Oncol. 2017 Apr;19(4):425-431. doi: 10.1007/s12094-016-1542-9. Epub 2016 Aug 23.
2
Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.原发性乳腺癌中CD44 mRNA和蛋白表达的临床病理相关性
Histopathology. 2003 Jun;42(6):546-54. doi: 10.1046/j.1365-2559.2003.01622.x.
3
Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence.结直肠癌侵袭前缘中 CD44 变体 6 表达缺失与早期复发相关。
World J Gastroenterol. 2012 Sep 7;18(33):4549-56. doi: 10.3748/wjg.v18.i33.4549.
4
High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.S100A4 的高表达与胃癌患者的淋巴结转移和不良预后相关。
Ann Surg Oncol. 2010 Jan;17(1):89-97. doi: 10.1245/s10434-009-0722-z. Epub 2009 Oct 10.
5
Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.E-钙黏蛋白、β-连环蛋白、CD44s和CD44v6在胃腺癌中的表达:与淋巴结转移的关系
Anticancer Res. 2003 Mar-Apr;23(2B):1581-8.
6
Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer.CD44v6在胃癌中的预后价值及功能作用评估。
J Cancer Res Clin Oncol. 2015 Oct;141(10):1809-17. doi: 10.1007/s00432-015-1964-8. Epub 2015 Mar 26.
7
Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.局部晚期直肠癌全直肠系膜切除术后CD44v6对治疗结果的预测
Cancer J. 2008 Jan-Feb;14(1):54-61. doi: 10.1097/PPO.0b013e3181629a67.
8
TPX2 expression is associated with poor survival in gastric cancer.TPX2的表达与胃癌患者的不良预后相关。
World J Surg Oncol. 2017 Jan 9;15(1):14. doi: 10.1186/s12957-016-1095-y.
9
Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.基质细胞衍生因子-1和CXCR4在结直肠癌中的表达促进肝转移。
Cancer Biomark. 2015;15(6):869-79. doi: 10.3233/CBM-150531.
10
Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.CD44v6而非E-钙黏蛋白或β-连环蛋白的表达影响原发性肺腺癌的预后。
J Pathol. 2000 Dec;192(4):427-32. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH741>3.0.CO;2-Z.

引用本文的文献

1
CD44v6 CAR-T Cells Target DNMT3A-Mutant AML: Synergistic Enhancement by Decitabine.CD44v6嵌合抗原受体T细胞靶向DNMT3A突变的急性髓系白血病:地西他滨的协同增强作用
Curr Med Sci. 2025 Aug 25. doi: 10.1007/s11596-025-00097-1.
2
CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.嵌合抗原受体 T 细胞对伴有 FLT3 或 DNMT3A 突变的 AML 的特异性。
Clin Transl Med. 2022 Sep;12(9):e1043. doi: 10.1002/ctm2.1043.
3
CD44v6 engages in colorectal cancer progression.CD44v6 参与结直肠癌的进展。

本文引用的文献

1
CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.CD44v6下调是结直肠癌预后不良的独立预后因素。
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14283-93. eCollection 2015.
2
Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.CD44v6的上调通过调节结肠癌SW480细胞中的自噬促进获得性化疗耐药。
Tumour Biol. 2016 Jul;37(7):8811-24. doi: 10.1007/s13277-015-4755-6. Epub 2016 Jan 9.
3
The expression of CD44v6 in colon: from normal to malignant.
Cell Death Dis. 2019 Jan 10;10(1):30. doi: 10.1038/s41419-018-1265-7.
4
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.新型工程化重组人抗 CD44v6 抗体用于放射免疫治疗的临床前评价。
Int J Oncol. 2018 Jun;52(6):1875-1885. doi: 10.3892/ijo.2018.4364. Epub 2018 Apr 11.
CD44v6在结肠中的表达:从正常到恶性。
Ann Diagn Pathol. 2016 Feb;20:19-23. doi: 10.1016/j.anndiagpath.2015.10.010. Epub 2015 Nov 10.
4
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.CD44 变体 6 与前列腺癌转移及化疗/放疗抵抗有关。
Prostate. 2014 May;74(6):602-17. doi: 10.1002/pros.22775. Epub 2014 Feb 12.
5
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.CD44v6 是驱动结肠癌转移的组成性和重编程癌症干细胞的标志物。
Cell Stem Cell. 2014 Mar 6;14(3):342-56. doi: 10.1016/j.stem.2014.01.009.
6
Tumour heterogeneity in the clinic.临床中的肿瘤异质性。
Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627.
7
The causes and consequences of genetic heterogeneity in cancer evolution.癌症进化中遗传异质性的原因和后果。
Nature. 2013 Sep 19;501(7467):338-45. doi: 10.1038/nature12625.
8
CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer.CD44v6 的表达与结直肠癌患者的间质表型和不良预后相关。
Oncol Rep. 2013 Apr;29(4):1570-8. doi: 10.3892/or.2013.2273. Epub 2013 Feb 5.
9
Cancer heterogeneity: implications for targeted therapeutics.癌症异质性:对靶向治疗的影响。
Br J Cancer. 2013 Feb 19;108(3):479-85. doi: 10.1038/bjc.2012.581. Epub 2013 Jan 8.
10
Osteopontin-enhanced hepatic metastasis of colorectal cancer cells.骨桥蛋白增强结直肠癌细胞的肝转移。
PLoS One. 2012;7(10):e47901. doi: 10.1371/journal.pone.0047901. Epub 2012 Oct 24.